505 related articles for article (PubMed ID: 20044011)
21. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
Hegde SS; Skinner R; Lewis SR; Krause KM; Blais J; Benton BM
J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
[TBL] [Abstract][Full Text] [Related]
22. Antimicrobial susceptibility of Clostridium difficile by E test.
Cheng SH; Chu FY; Lo SH; Lu JJ
J Microbiol Immunol Infect; 1999 Jun; 32(2):116-20. PubMed ID: 11561576
[TBL] [Abstract][Full Text] [Related]
23. Time-kill kinetics of cadazolid and comparator antibacterial agents against different ribotypes of Clostridium difficile.
Skinner K; Birchall S; Corbett D; Thommes P; Locher HH
J Med Microbiol; 2018 Sep; 67(9):1402-1409. PubMed ID: 30052178
[TBL] [Abstract][Full Text] [Related]
24. Activity of telavancin compared to other agents against coagulase-negative staphylococci with different resistotypes by time kill.
Lin G; Pankuch GA; Appelbaum PC; Kosowska-Shick K
Diagn Microbiol Infect Dis; 2012 Jul; 73(3):287-9. PubMed ID: 22575272
[TBL] [Abstract][Full Text] [Related]
25. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin.
Al-Nassir WN; Sethi AK; Nerandzic MM; Bobulsky GS; Jump RL; Donskey CJ
Clin Infect Dis; 2008 Jul; 47(1):56-62. PubMed ID: 18491964
[TBL] [Abstract][Full Text] [Related]
26. Ambush of Clostridium difficile spores by ramoplanin: activity in an in vitro model.
Kraus CN; Lyerly MW; Carman RJ
Antimicrob Agents Chemother; 2015 May; 59(5):2525-30. PubMed ID: 25691641
[TBL] [Abstract][Full Text] [Related]
27. Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators.
Freeman J; Vernon J; Vickers R; Wilcox MH
Antimicrob Agents Chemother; 2016 Jan; 60(1):689-92. PubMed ID: 26552981
[TBL] [Abstract][Full Text] [Related]
28. Fidaxomicin inhibits spore production in Clostridium difficile.
Babakhani F; Bouillaut L; Gomez A; Sears P; Nguyen L; Sonenshein AL
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S162-9. PubMed ID: 22752866
[TBL] [Abstract][Full Text] [Related]
29. A novel method for imaging the pharmacological effects of antibiotic treatment on Clostridium difficile.
Endres BT; Bassères E; Memariani A; Chang L; Alam MJ; Vickers RJ; Kakadiaris IA; Garey KW
Anaerobe; 2016 Aug; 40():10-4. PubMed ID: 27108094
[TBL] [Abstract][Full Text] [Related]
30. In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin.
Leeds JA; Sachdeva M; Mullin S; Barnes SW; Ruzin A
J Antimicrob Chemother; 2014 Jan; 69(1):41-4. PubMed ID: 23887866
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model.
Baines SD; Noel AR; Huscroft GS; Todhunter SL; O'Connor R; Hobbs JK; Freeman J; Lovering AM; Wilcox MH
J Antimicrob Chemother; 2011 Jul; 66(7):1537-46. PubMed ID: 21504940
[TBL] [Abstract][Full Text] [Related]
32. In vitro antimicrobial activity of telavancin against methicillin-resistant Staphylococcus aureus clinical isolates from Japan (2006).
Hatano K; Matsuzaki K; Sato Y; Kobayashi I; Yamaguchi K
J Antibiot (Tokyo); 2007 Nov; 60(11):709-12. PubMed ID: 18057701
[TBL] [Abstract][Full Text] [Related]
33. Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection.
Sullivan KM; Spooner LM
Ann Pharmacother; 2010 Feb; 44(2):352-9. PubMed ID: 20071495
[TBL] [Abstract][Full Text] [Related]
34. Emergence of reduced susceptibility to metronidazole in Clostridium difficile.
Baines SD; O'Connor R; Freeman J; Fawley WN; Harmanus C; Mastrantonio P; Kuijper EJ; Wilcox MH
J Antimicrob Chemother; 2008 Nov; 62(5):1046-52. PubMed ID: 18693234
[TBL] [Abstract][Full Text] [Related]
35. Antibacterial activity of rhodomyrtone on Clostridium difficile vegetative cells and spores in vitro.
Srisuwan S; Mackin KE; Hocking D; Lyras D; Bennett-Wood V; Voravuthikunchai SP; Robins-Browne RM
Int J Antimicrob Agents; 2018 Nov; 52(5):724-729. PubMed ID: 30145248
[TBL] [Abstract][Full Text] [Related]
36. Analysis of metronidazole susceptibility in different Clostridium difficile PCR ribotypes.
Moura I; Spigaglia P; Barbanti F; Mastrantonio P
J Antimicrob Chemother; 2013 Feb; 68(2):362-5. PubMed ID: 23104495
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity of OPT-80 against Clostridium difficile.
Ackermann G; Löffler B; Adler D; Rodloff AC
Antimicrob Agents Chemother; 2004 Jun; 48(6):2280-2. PubMed ID: 15155234
[TBL] [Abstract][Full Text] [Related]
38. Bactericidal activity of daptomycin versus vancomycin in the presence of human albumin against vancomycin-susceptible but tolerant methicillin-resistant Staphylococcus aureus (MRSA) with daptomycin minimum inhibitory concentrations of 1-2microg/mL.
Torrico M; Giménez MJ; González N; Alou L; Sevillano D; Cafini F; Prieto J; Cleeland R; Aguilar L
Int J Antimicrob Agents; 2010 Feb; 35(2):131-7. PubMed ID: 20006469
[TBL] [Abstract][Full Text] [Related]
39. Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.
Lubenko IY; Strukova EV; Smirnova MV; Vostrov SN; Portnoy YA; Zinner SH; Firsov AA
J Antimicrob Chemother; 2008 Nov; 62(5):1065-9. PubMed ID: 18635520
[TBL] [Abstract][Full Text] [Related]
40. Metronidazole resistance in Clostridium difficile.
Johnson S; Sanchez JL; Gerding DN
Clin Infect Dis; 2000 Aug; 31(2):625-6. PubMed ID: 10987742
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
